UNSPSC 51183400: Antidiabetic and hyperglycemic glinides

This classification denotes benzoic-acid-based compounds that increased pro-insulin secretion, substances called glinides (after 4-(2-(5-chloro-2-methoxybenzamido)ethyl)benzoic acid, or meglitinide), thus the term ANTIDIABETIC AND HYPERGLYCEMIC GLINIDES.

UNSPSC 51183400 Antidiabetic and hyperglycemic glinides is a Class code covering prescription medications used to manage blood sugar levels in diabetic patients. State and local governments procure these drugs primarily through health departments, Medicaid agencies, public health clinics, and institutional healthcare systems including county hospitals and correctional facilities. The medications in this class—principally meglitinides such as repaglinide and nateglinide—are short-acting insulin secretagogues used as monotherapy or in combination regimens for Type 2 diabetes management. Procurement typically occurs through competitive bid cycles, cooperative purchasing agreements, and state pharmaceutical formulary contracts that establish pricing and volume commitments across multiple service points within a jurisdiction.

The source provides no recent state and local contract opportunities tagged to this code, preventing characterization of current geographic activity or issuing-body concentration. Without posted solicitations, opportunities, or awarded contracts in the recent-opportunities data, no representative RFP, RFQ, IFB, or ITB examples can be identified. If your firm actively pursues pharmaceutical supply contracts with state Medicaid programs, county health systems, or public hospital networks, direct outreach to procurement offices in high-volume states (typically those with large Medicaid populations and centralized drug formulary management) remains the primary business development pathway, as this code does not currently reflect visible recent market activity in state and local procurement channels.